Tisdag 6 Maj | 05:42:32 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-06 08:30 Kvartalsrapport 2025-Q3
2025-07-24 08:30 Kvartalsrapport 2025-Q2
2025-05-23 N/A X-dag ordinarie utdelning MNTC 0.00 SEK
2025-05-22 N/A Årsstämma
2025-05-08 08:30 Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-07-23 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning MNTC 0.00 SEK
2024-05-23 - Årsstämma
2024-05-03 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-20 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning MNTC 0.00 SEK
2023-05-11 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-03 - Bokslutskommuniké 2022
2022-10-26 - Kvartalsrapport 2022-Q3
2022-07-21 - Kvartalsrapport 2022-Q2
2022-04-28 - X-dag ordinarie utdelning MNTC 0.00 SEK
2022-04-28 - Kvartalsrapport 2022-Q1
2022-04-27 - Årsstämma
2022-02-03 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-22 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning MNTC 0.00 SEK
2021-05-06 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-04 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning MNTC 0.00 SEK
2020-05-27 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-25 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-08-28 - Extra Bolagsstämma 2019

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Mentice är verksamt inom medicinteknik. Bolaget utvecklar medicinska instrument för endovaskulär simulering samt för träningstillfällen inom kirurgi. Programmen är utvecklade för att användas i utbildningssyfte bland sjukhus och institut. Störst verksamhet återfinns inom Nordamerika och Europa. Utöver huvudverksamheten erbjuds möjligheter till leasing, support, samt teknisk service. Huvudkontoret ligger i Göteborg.
2023-02-03 08:30:00

Continued strong order intake and improved cashflow

Fourth quarter (October–December 2022)
• Order intake amounted to 90.3 (73.8) MSEK.
• Orderbook by the end of the period was 126.0 (87.1) MSEK.
• Net sales amounted to 68.7 (67.7) MSEK.
• Earnings before depreciation and amortization (EBITDA) totaled 11.5 (12.0) MSEK.
• Net income for the period amounted to 2.1 (-4.2) MSEK.
• Earnings per share (EPS) was 0.08 (-0.17) SEK.
• Cash flow from operating activities totaled 26.0 (7.4) MSEK.

Full-year (January–December 2022)
• Order intake amounted to 252.2 (205.6) MSEK.
• Net sales amounted to 218.0 (185.1) MSEK.
• Earnings before depreciation and amortization (EBITDA) totaled -3.9 (2.5) MSEK.
• Net income for the period amounted to -30.7 (-29.2) MSEK.
• Earnings per share (EPS) was -1.22 (-1.18) SEK.
• Cash flow from operating activities totaled 14.9 (-5.1) MSEK.

CEO Göran Malmberg comments:
The fourth quarter of 2022 concluded the year as a year of continued growth, driven by strong growth from both the hospital and strategic alliances business areas but also partly fuelled by the exchange rate. For the fourth quarter, we are pleased to see the initial effects of cost-saving activities implemented during the third quarter. We have reduced external costs, improved our cash position, increased operational cash flow, and also a small but positive EPS.

For the full year, we have delivered growth in net sales of almost 18% (including currency effects), and we reached a new all-time high of 218.0 MSEK for net sales in 2022. At the same time, we have increased our order intake from 205 MSEK to 252 (23%), and our order book at the end of 2022 was 126 (87) MSEK, an increase of 45%.

We are also pleased to see that, despite improvement during 2021, we have continued to improve our margins for 2022, resulting in an average gross margin of 85.5%, up from 81.0% in 2021. This is driven by price adjustments but also our focus on product mix and margin on deal levels. Currency exchange rates also have a positive effect on margins.

Webcast presentation of the year-end report
The presentation of the Year-end Report Q4 for the period October – December 2022 will be held on February 3rd, 2023, at 10:00 CET. The live broadcast is followed by a Q&A moderated by Redeye’s analyst Christian Binder. For more information on how to register, please visit https://investor.mentice.com/.

The presentation will be held in English. Participants are advised to register at least a few minutes in advance.